Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

GW4064, an Agonist of Farnesoid X Receptor, Represses CYP3A4 Expression in Human Hepatocytes by Inducing Small Heterodimer Partner Expression

Shu Zhang, Xian Pan and Hyunyoung Jeong
Drug Metabolism and Disposition May 2015, 43 (5) 743-748; DOI: https://doi.org/10.1124/dmd.114.062836
Shu Zhang
Department of Pharmacy Practice (H.J.) and Department of Biopharmaceutical Sciences (S.Z., X.P., H.J.), College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xian Pan
Department of Pharmacy Practice (H.J.) and Department of Biopharmaceutical Sciences (S.Z., X.P., H.J.), College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyunyoung Jeong
Department of Pharmacy Practice (H.J.) and Department of Biopharmaceutical Sciences (S.Z., X.P., H.J.), College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 43 no. 5 743-748
DOI 
https://doi.org/10.1124/dmd.114.062836
PubMed 
25725071

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received December 19, 2014
  • Accepted February 27, 2015
  • Published online March 27, 2015.

Article Versions

  • Earlier version (February 27, 2015 - 10:26).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Shu Zhang,
  2. Xian Pan, and
  3. Hyunyoung Jeong
  1. Department of Pharmacy Practice (H.J.) and Department of Biopharmaceutical Sciences (S.Z., X.P., H.J.), College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois
  1. Address correspondence to:
    Hyunyoung Jeong, PharmD, PhD, Department of Pharmacy Practice (MC 886), College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612. E-mail: yjeong{at}uic.edu
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: February 2015 to January 2021

AbstractFullPdf
Feb 2015126022
Mar 20156059205
Apr 20154673563
May 20151872649
Jun 20151361526
Jul 2015761227
Aug 2015832117
Sep 201564816
Oct 201551810
Nov 20157866
Dec 2015391215
Jan 2016461016
Feb 201631119
Mar 2016312018
Apr 2016251012
May 2016421119
Jun 2016291415
Jul 2016312549
Aug 2016351817
Sep 201619119
Oct 201673817
Nov 201683223
Dec 201655355
Jan 201742719
Feb 20172267
Mar 201793315
Apr 2017132721
May 2017193118
Jun 2017113120
Jul 2017122125
Aug 2017243021
Sep 20171318531
Oct 2017119217
Nov 2017172616
Dec 2017213220
Jan 2018193717
Feb 2018142326
Mar 2018183019
Apr 2018214019
May 2018143621
Jun 2018133521
Jul 2018163520
Aug 2018121415
Sep 201813368
Oct 201810147
Nov 20188239
Dec 2018102339
Jan 2019111615
Feb 201914716
Mar 2019153029
Apr 2019204432
May 2019111223
Jun 201981825
Jul 201981720
Aug 201982817
Sep 2019102426
Oct 201953227
Nov 2019113021
Dec 201974315
Jan 202072824
Feb 202053724
Mar 202075729
Apr 202043315
May 202012919
Jun 202032713
Jul 202062611
Aug 202012121
Sep 202021811
Oct 202073816
Nov 202052521
Dec 202033129
Jan 20214158

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 43 (5)
Drug Metabolism and Disposition
Vol. 43, Issue 5
1 May 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
GW4064, an Agonist of Farnesoid X Receptor, Represses CYP3A4 Expression in Human Hepatocytes by Inducing Small Heterodimer Partner Expression
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

CYP3A4 Repression by FXR Agonist

Shu Zhang, Xian Pan and Hyunyoung Jeong
Drug Metabolism and Disposition May 1, 2015, 43 (5) 743-748; DOI: https://doi.org/10.1124/dmd.114.062836

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

CYP3A4 Repression by FXR Agonist

Shu Zhang, Xian Pan and Hyunyoung Jeong
Drug Metabolism and Disposition May 1, 2015, 43 (5) 743-748; DOI: https://doi.org/10.1124/dmd.114.062836
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
  • Gene expression profile of human intestinal epithelial cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics